Imagine catching diseases before they strike, saving lives and billions. That’s the power of seed-stage healthcare innovation we’re fueling.

The healthcare landscape is at a tipping point. Costs are skyrocketing, with U.S. spending projected to hit nearly $7.5 trillion by 2031, yet preventable diseases claim millions of lives annually. At Seed, we’re not just observers. We’re catalysts and our mission is clear: disrupt the status quo by uniting financial firepower with healthcare expertise to drive early detection and prevention.

We focus on Seed to Series A rounds for startups in digital health, medtech, healthcare IT, and services. These aren’t random bets, they’re targeted at solutions that prioritize proactive care over reactive treatment. Think AI-driven diagnostics that forecast diseases like weather patterns, or biohacking tools enabling personalized longevity plans. Our approach leverages an exclusive network of providers and industry leaders to propel portfolio companies forward, ensuring they navigate regulations, scale efficiently, and deliver real impact.

Each of our investments align with the latest trends driving healthcare forward. In 2024, U.S. healthcare VC funding reached $23 billion, with AI driving the surge. Healthcare AI startups captured a growing share, building on 41% of digital health funding that year. The biohacking market is surging from $24.81 billion in 2024 to $69.09 billion by 2030 at a 18.95% CAGR. We’ve seen Q1 2025 digital health funding hit $3 billion in the U.S., led by AI-powered innovations in telehealth and care management. Our fund taps into these waves, backing innovators who blend tech with human-centric care to cut costs, potentially saving $200-360 billion through AI and digital transformation alone.

The opportunity is massive. With about one-third of health execs prioritizing technology investments in 2025, but many lacking resources, and value-based care tying around 50% of payments to quality, early-stage investors like us are positioned to generate outsized returns while transforming lives. We’re shifting from “growth at all costs” to sustainable profitability, especially as economic conditions stabilize post-rate adjustments.

A critical element of our strategy is ensuring that innovation translates into real-world impact through successful commercialization. We believe that groundbreaking ideas must reach patients and healthcare providers to truly improve health outcomes and generate sustainable value. To achieve this, we emphasize startups with clear go-to-market strategies, strong pathways to monetization, and scalable business models.

Our board and clinical team play a vital role in this process. Comprising seasoned healthcare executives, clinical scientists, and commercialization experts, they provide hands-on guidance in navigating regulatory pathways, establishing reimbursement models, and building revenue streams. This expertise is essential in accelerating market entry, reducing time-to-impact, and ensuring that innovations don’t just stay in the lab but reach the people who need them most.

And it’s not all just about the numbers, it’s also about the startups, the founders stories, and the real-life impact being created today. Imagine a startup using multimodal AI to detect chronic illnesses early, extending healthy lifespans. Or medtech enabling bioprinted organs by 2035, eradicating hereditary diseases. These aren’t sci-fi; they’re the realities we’re funding today.

If you’re a founder building in preventive healthcare or an investor eyeing high-impact returns, let’s talk.